Partnering with us
Akston is building deep partnerships around the world. We partner with Animal Health companies that can take our therapeutics to market or have their own candidates that we can help develop and manufacture.
We offer partnership opportunities to established Veterinary Pharmaceutical companies and start-ups that would benefit from our Animal Health-dedicated product development and manufacturing resources to advance their own protein therapeutics.
If you are interested in speaking with us about partnering opportunities, please contact us.
We have licensed our once-a-week veterinary insulins to Dechra Pharmaceutical PLC. Vakston is developing our human vaccine candidates and Diamune, Inc. is licensed to develop our human diabetes candidates. We maintain close involvement with our partners throughout the development process.
Dechra is a global specialist veterinary pharmaceuticals and related products business. Their expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Additional information is available at dechra.com
QipWorks is a full-service IP strategic advisory firm that partners with technology companies, innovators, and investors to build, manage and utilize IP portfolios. The company provides extensive expertise in patent portfolio development and an intimate understanding of the rigor required at all stages of the innovation and patent lifecycle. Additional information is available at qipworks.com
Vakston, Inc. is a subsidiary of Akston Biosciences, Inc. focused on human vaccine candidates, including a Covid-19 vaccine that is thermostable, low-cost, and has a ‘universal’ booster vaccine capability. Additional information is available at vakston.com
Diamune Therapeutics, Inc. is a subsidiary of Akston Biosciences, Inc. focused on human diabetes candidates, including Type 1 diabetes intervention. Additional information is available at diamune.com